Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,104,206 articles, preprints and more)

Search results

1-25 of 38 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.
Toh HC, Yang MH, Wang HM, Hsieh CY, Chitapanarux I, Ho KF, Hong RL, Ang MK, Colevas AD, Sirachainan E, Lertbutsayanukul C, Ho GF, Nadler E, Algazi A, Lulla P, Wirth LJ, Wirasorn K, Liu YC, Ang SF, [...] Samol J
Ann Oncol, S0923-7534(24)03923-1, 04 Sep 2024
Cited by: 1 article | PMID: 39241963
Add to export list
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.
Poh ME, Balakrishnan S, Tan SN, Zainal Abidin MA, Liam CK, Tan JL, Pang YK, Alaga A, Tho LM, How SH
Transl Lung Cancer Res, 13(7):1649-1659, 23 Jul 2024
Cited by: 0 articles | PMID: 39118879 | PMCID: PMC11304135
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, [...] INSIGHT 2 investigators
Lancet Oncol, 25(8):989-1002, 01 Aug 2024
Cited by: 1 article | PMID: 39089305
Add to export list
Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
Poh ME, Chai CS, Liam CK, Ho GF, Pang YK, Hasbullah HH, Tho LM, Muhamad Nor I, Ho KF, Thiagarajan M, Samsudin A, Omar A, Ong CK, Soon SY, Tan SN, How SH
Transl Lung Cancer Res, 13(2):307-320, 28 Feb 2024
Cited by: 1 article | PMID: 38496703 | PMCID: PMC10938108
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The potential role of artificial intelligence-assisted chest X-ray imaging in detecting early-stage lung cancer in the community-a proposed algorithm for lung cancer screening in Malaysia.
Sachithanandan A, Lockman H, Azman RR, Tho LM, Ban EZ, Ramon V
Med J Malaysia, 79(1):9-14, 01 Jan 2024
Cited by: 0 articles | PMID: 38287751
Add to export list
Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country.
Poh ME, How SH, Ho GF, Pang YK, Hasbullah HH, Tho LM, Muhamad Nor I, Lim BC, Ho KF, Thiagarajan M, Samsudin A, Omar A, Ong CK, Soon SY, Tan JYK, Zainal Abidin MA
Cancer Manag Res, 15:31-41, 13 Jan 2023
Cited by: 1 article | PMID: 36660237 | PMCID: PMC9844146
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
Chow YP, Zainul Abidin N, Kow KS, Tho LM, Wong CL
PLoS One, 17(10):e0276161, 18 Oct 2022
Cited by: 0 articles | PMID: 36256645 | PMCID: PMC9578623
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country.
How SH, Tho LM, Liam CK, Hasbullah HH, Ho GF, Muhammad Nor I, Poh ME, Ho KF, Thiagarajan M, Samsudin A, Omar A, Ong CK, Pang YK, Soon SY
Thorac Cancer, 13(11):1676-1683, 03 May 2022
Cited by: 4 articles | PMID: 35502623 | PMCID: PMC9161340
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia.
How SH, Liam CK, Zainal Abidin MA, Hasbullah HH, Tho LM, Ho GF, Muhamad Nor I, Pang YK, Ho KF, Thiagarajan M, Ariffin R, Samsudin A, Omar A, Tan SN, Ong CK, Soon SY, Poh ME
Cancer Manag Res, 14:1995-2005, 16 Jun 2022
Cited by: 3 articles | PMID: 35733510 | PMCID: PMC9208817
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.
F Smit E, Dooms C, Raskin J, Nadal E, Tho LM, Le X, Mazieres J, S Hin H, Morise M, W Zhu V, Tan D, H Holmberg K, Ellers-Lenz B, Adrian S, Brutlach S, Schumacher KM, Karachaliou N, Wu YL
Future Oncol, 18(9):1039-1054, 17 Dec 2021
Cited by: 18 articles | PMID: 34918545
Add to export list
Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes.
Yoon SY, Wong SW, Lim J, Ahmad S, Mariapun S, Padmanabhan H, Hassan NT, Lau SY, Ch'ng GS, Haniffa M, Ong WP, Rethanavelu K, Moey LH, Keng WT, Omar J, Mohd Abas MN, Yong CM, Ramasamy V, Md Noor MR, [...] Teo SH
J Med Genet, 59(3):220-229, 01 Feb 2021
Cited by: 8 articles | PMID: 33526602
Add to export list
Morphine use for cancer pain: A strong analgesic used only at the end of life? A qualitative study on attitudes and perceptions of morphine in patients with advanced cancer and their caregivers.
Ho JFV, Yaakup H, Low GSH, Wong SL, Tho LM, Tan SB
Palliat Med, 34(5):619-629, 27 Feb 2020
Cited by: 7 articles | PMID: 32103707 | PMCID: PMC7238510
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Lung Cancer in Malaysia.
Rajadurai P, How SH, Liam CK, Sachithanandan A, Soon SY, Tho LM
J Thorac Oncol, 15(3):317-323, 01 Mar 2020
Cited by: 12 articles | PMID: 32093853
Add to export list
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC.
Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F
J Thorac Oncol, 15(3):324-343, 13 Nov 2019
Cited by: 27 articles | PMID: 31733357
Add to export list Review
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
Rajadurai P, Cheah PL, How SH, Liam CK, Annuar MAA, Omar N, Othman N, Marzuki NM, Pang YK, Bustamam RSA, Tho LM
Lung Cancer, 136:65-73, 05 Aug 2019
Cited by: 4 articles | PMID: 31446227
Add to export list Review
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G, KEYNOTE-042 Investigators
Lancet, 393(10183):1819-1830, 04 Apr 2019
Cited by: 1597 articles | PMID: 30955977
Add to export list
Inadequate treatment practices for pain relief and adverse event management in cancer patients across 10 countries/regions in Asia: a call for greater efforts to improve standards for patient care.
Ho KY, Ahn JS, Calimag MM, Chao TC, Kim YC, Moon H, Tho LM, Xia ZJ, You D
Asia Pac J Clin Oncol, 14(3):159-166, 03 Jul 2017
Cited by: 6 articles | PMID: 28670820
Add to export list
Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries.
ACHEON Working Group, Kim YC, Ahn JS, Calimag MM, Chao TC, Ho KY, Tho LM, Xia ZJ, Ward L, Moon H, Bhagat A
Cancer Med, 4(8):1196-1204, 27 Apr 2015
Cited by: 40 articles | PMID: 25914253 | PMCID: PMC4559031
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Prognostic factors in patients with non-small cell lung carcinoma and brain metastases: a Malaysian perspective.
Tang WH, Alip A, Saad M, Phua VC, Chandran H, Tan YH, Tan YY, Kua VF, Wahid MI, Tho LM
Asian Pac J Cancer Prev, 16(5):1901-1906, 01 Jan 2015
Cited by: 2 articles | PMID: 25773842
Add to export list
Closing the global cancer divide--performance of breast cancer care services in a middle income developing country.
Lim GC, Aina EN, Cheah SK, Ismail F, Ho GF, Tho LM, Yip CH, Taib NA, Chong KJ, Dharmaratnam J, Abdullah MM, Mohamed AK, Ho KF, Ratnavelu K, Lim CM, Leong KW, Wahid IA, Lim TO, HPMRS Breast Cancer Study Group
BMC Cancer, 14:212, 20 Mar 2014
Cited by: 17 articles | PMID: 24650245 | PMCID: PMC3994538
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma.
Venugopal B, Ansari J, Aitchison M, Tho LM, Campbell R, Jones RJ
BMC Urol, 13:26, 21 May 2013
Cited by: 6 articles | PMID: 23688003 | PMCID: PMC3679738
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The influence of MRI scan position on patients with oropharyngeal cancer undergoing radical radiotherapy.
Hanvey S, McJury M, Tho LM, Glegg M, Thomson M, Grose D, James A, Rizwanullah M, Paterson C, Foster J
Radiat Oncol, 8:129, 28 May 2013
Cited by: 19 articles | PMID: 23714579 | PMCID: PMC3681609
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Defining optimal cut-off values and research methodology for evaluating systemic inflammatory markers in clinical outcome prediction.
Tho LM, Huh J, Sanders I, Carruthers R, Han S, McDonald A
World J Surg, 36(11):2742-3; author reply 2744-5, 01 Nov 2012
Cited by: 1 article | PMID: 22717538
Add to export list
Treatment outcome for nasopharyngeal carcinoma in University Malaya Medical Centre from 2004-2008.
Chee Ee Phua V, Loo WH, Yusof MM, Wan Ishak WZ, Tho LM, Ung NM
Asian Pac J Cancer Prev, 14(8):4567-4570, 01 Jan 2013
Cited by: 11 articles | PMID: 24083703
Add to export list
Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer.
Carruthers R, Tho LM, Brown J, Kakumanu S, McCartney E, McDonald AC
Colorectal Dis, 14(10):e701-7, 01 Oct 2012
Cited by: 88 articles | PMID: 22731833
Add to export list

1-25 of 38 results

1 2

Search life-sciences literature (45,104,206 articles, preprints and more)

Search results

Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial.

Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.

Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?

The potential role of artificial intelligence-assisted chest X-ray imaging in detecting early-stage lung cancer in the community-a proposed algorithm for lung cancer screening in Malaysia.

Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country.

Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.

Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country.

Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia.

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.

Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes.

Morphine use for cancer pain: A strong analgesic used only at the end of life? A qualitative study on attitudes and perceptions of morphine in patients with advanced cancer and their caregivers.

Lung Cancer in Malaysia.

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC.

Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Inadequate treatment practices for pain relief and adverse event management in cancer patients across 10 countries/regions in Asia: a call for greater efforts to improve standards for patient care.

Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries.

Prognostic factors in patients with non-small cell lung carcinoma and brain metastases: a Malaysian perspective.

Closing the global cancer divide--performance of breast cancer care services in a middle income developing country.

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma.

The influence of MRI scan position on patients with oropharyngeal cancer undergoing radical radiotherapy.

Defining optimal cut-off values and research methodology for evaluating systemic inflammatory markers in clinical outcome prediction.

Treatment outcome for nasopharyngeal carcinoma in University Malaya Medical Centre from 2004-2008.

Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer.

Partnerships & funding